ArticleWorld journal of hepatology2025
Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2).Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Review
- Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment.The Journal of infectious diseases · 2026Article
- HBV and HCV Burden in a Greek Hospital Population (2018-2024): Trends and Correlates of HBsAg and Anti-HCV Positivity.Pathogens (Basel, Switzerland) · 2026Article
- Treatment with Direct-Acting Antivirals in Patients with HCV Infection After Liver Transplantation.Journal of clinical medicine · 2026Article
- Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals.World journal of hepatology · 2025Article
- Gender disparities in hepatitis C treatment: A call for tailored approaches.World journal of hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex is one of the known factors influencing the risk of hepatitis C virus (HCV) infection and the natural course of the disease.
aimTo evaluate sex-related differences in the characteristics and outcomes of direct-acting antiviral (DAA) treatment in HCV-infected patients.
methodsThe study included consecutive 9457 women and 9529 men, treated with DAA for chronic HCV infection from July 2015 to the end of 2023 whose data were collected in the nationwide multicenter retrospective Epiter-2 project. Women were divided into pre-menopausal (15-44 years), menopausal (45-55 years) and post-menopausal (> 55 years) and compared with age-matched men.
resultsRegardless of age, women had a significantly lower body mass index, prevalence of genotype 3 infection and proportion of cirrhosis compared to men. Psychiatric disorders (except depression), hepatitis B virus and human immunodeficiency virus co-infections, as well as alcohol and drug addiction, were significantly less common in women than in men in all age groups. The sustained virologic response was significantly higher in women compared to men in each age group and amounted to 98.4% and 96.6%, respectively (
conclusionDAA treatment is more effective in women than in men, regardless of age, but in postmenopausal women, the effectiveness is relatively the lowest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.